Evogene (NASDAQ:EVGN) Issues Earnings Results, Beats Estimates By $0.10 EPS

Evogene (NASDAQ:EVGN) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.10, Zacks reports. Evogene had a negative return on equity of 109.96% and a negative net margin of 211.61%.

Evogene Stock Performance

NASDAQ:EVGN traded up $0.03 during trading on Thursday, reaching $1.20. The company’s stock had a trading volume of 16,050 shares, compared to its average volume of 646,828. The firm has a market cap of $6.44 million, a price-to-earnings ratio of -0.53 and a beta of 1.50. The firm has a 50 day moving average of $1.23 and a 200-day moving average of $1.27. Evogene has a 12 month low of $0.95 and a 12 month high of $2.42.

Institutional Trading of Evogene

A hedge fund recently raised its stake in Evogene stock. Citadel Advisors LLC grew its holdings in shares of Evogene Ltd. (NASDAQ:EVGN) by 169.4% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 57,575 shares of the biotechnology company’s stock after acquiring an additional 36,206 shares during the quarter. Citadel Advisors LLC owned 1.07% of Evogene worth $66,000 at the end of the most recent quarter. 10.40% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Evogene in a research note on Wednesday, October 8th. Alliance Global Partners raised shares of Evogene to a “strong-buy” rating in a research note on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $3.50.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.